XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.3
Insider Trading Arrangements
9 Months Ended
Sep. 30, 2023
shares
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement

On September 12, 2023, Dr. Steven Ketchum, President of R&D and Chief Scientific Officer of the Company, adopted a trading arrangement for the sale of securities of the Company's common stock, or a Rule 10b5-1 Trading Plan, that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Dr. Ketchum's Rule 10b5-1 Trading Plan, which has a plan end date of December 31, 2025, provides for the sale of up to 1,598,749 shares of common stock pursuant to the terms of the plan.

Name Dr. Steven Ketchum
Title President of R&D and Chief Scientific Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date September 12, 2023
Termination Date December 31, 2025
Aggregate Available 1,598,749